BlackRock
GLUE icon

BlackRock’s Monte Rosa Therapeutics GLUE Stock Holding History

BlackRock’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166M Buy
6,843,087
+1,205,403
+21% +$22.8M ﹤0.01% 1909
2026
Q1 		$92.7M Buy
5,637,684
+1,456,523
+35% +$27.9M ﹤0.01% 2158
2025
Q4 		$65.6M Buy
4,181,161
+366,028
+10% +$4.93M ﹤0.01% 2357
2025
Q3 		$28.3M Sell
3,815,133
-31,321
-0.8% -$166K ﹤0.01% 2872
2025
Q2 		$17.3M Buy
3,846,454
+79,742
+2% +$356K ﹤0.01% 3115
2025
Q1 		$17.5M Sell
3,766,712
-73,452
-2% -$450K ﹤0.01% 3014
2024
Q4 		$26.7M Buy
3,840,164
+938,673
+32% +$7.04M ﹤0.01% 2860
2024
Q3 		$15.4M Buy
2,901,491
+541,398
+23% +$2.73M ﹤0.01% 3191
2024
Q2 		$8.83M Buy
2,360,093
+53,084
+2% +$271K ﹤0.01% 3441
2024
Q1 		$16.3M Sell
2,307,009
-64,971
-3% -$385K ﹤0.01% 3105
2023
Q4 		$13.4M Sell
2,371,980
-1,322,688
-36% -$5.19M ﹤0.01% 3243
2023
Q3 		$17.7M Sell
3,694,668
-165,688
-4% -$1.07M ﹤0.01% 3005
2023
Q2 		$26.4M Buy
3,860,356
+250,935
+7% +$1.62M ﹤0.01% 2864
2023
Q1 		$28.1M Buy
3,609,421
+10,885
+0.3% +$75.7K ﹤0.01% 2794
2022
Q4 		$27.4M Buy
3,598,536
+128,304
+4% +$1.07M ﹤0.01% 2858
2022
Q3 		$28.4M Buy
3,470,232
+157,663
+5% +$1.45M ﹤0.01% 2838
2022
Q2 		$32M Buy
3,312,569
+184,177
+6% +$1.85M ﹤0.01% 2800
2022
Q1 		$43.9M Buy
3,128,392
+774,628
+33% +$10.8M ﹤0.01% 2663
2021
Q4 		$48.1M Buy
2,353,764
+285,087
+14% +$5.97M ﹤0.01% 2687
2021
Q3 		$46.1M Buy
2,068,677
+518,792
+33% +$14.9M ﹤0.01% 2710
2021
Q2 		$35.2M Buy
+1,549,885
New +$31.6M ﹤0.01% 2933

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock's GLUE Position: Q2 2026 in Review

BlackRock increased its Monte Rosa Therapeutics (GLUE) stake by 21% in Q2 2026, buying an estimated $22.8M and bringing the position to 6,843,087 shares worth $166M. The position accounts for ﹤0.01% of the portfolio, ranked #1909.

BlackRock first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • BlackRock held 6,843,087 shares of Monte Rosa Therapeutics worth $166M as of Q2 2026.
  • BlackRock bought 1,205,403 Monte Rosa Therapeutics shares in Q2 2026, an estimated $22.8M.
  • Monte Rosa Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1909 holding.
  • BlackRock first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.